Letters Avastin in macular degeneration

Bevacizumab must be specially prepared for intraocular use

BMJ 2013; 347 doi: https://doi.org/10.1136/bmj.f5032 (Published 14 August 2013) Cite this as: BMJ 2013;347:f5032
  1. Ilias Georgalas, assistant professor, ophthalmic surgeon1,
  2. Dimitris Papaconstantinou, assistant professor1,
  3. Theodore Paraskevopoulos, ophthalmic surgeon1,
  4. Chryssanthi Koutsandrea, associate professor1
  1. 1Department of Ophthalmology, University of Athens, Athens, Greece
  1. igeorgalas{at}yahoo.com

Torjesen clearly sums up the results of a recent trial showing that off-label use of bevacizumab (Avastin) is as effective as the more expensive licensed treatment for wet age related macular degeneration—ranibizumab (Lucentis).1 2 This will provide an …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe